tradingkey.logo

ADMA Biologics Inc

ADMA
View Detailed Chart
16.430USD
+0.490+3.07%
Close 02/06, 16:00ETQuotes delayed by 15 min
3.92BMarket Cap
18.51P/E TTM

ADMA Biologics Inc

16.430
+0.490+3.07%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.07%

5 Days

-5.03%

1 Month

-10.41%

6 Months

-11.38%

Year to Date

-9.92%

1 Year

-2.90%

View Detailed Chart

TradingKey Stock Score of ADMA Biologics Inc

Currency: USD Updated: 2026-02-06

Key Insights

ADMA Biologics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.67.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ADMA Biologics Inc's Score

Industry at a Glance

Industry Ranking
32 / 159
Overall Ranking
95 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

ADMA Biologics Inc Highlights

StrengthsRisks
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 176.77% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 18.51, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 228.97M shares, increasing 0.04% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 3.19K shares of this stock.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
25.667
Target Price
+61.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ADMA Biologics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ADMA Biologics Inc Info

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Ticker SymbolADMA
CompanyADMA Biologics Inc
CEOGrossman (Adam S)
Websitehttps://www.admabiologics.com/
KeyAI